Biosimilars and Innovation Poised to Fuel Next Growth Phase for Indian Pharma, Says Vishal Manchanda.
The Indian pharmaceutical industry is undergoing a significant transformation, moving beyond the stability offered by traditional generic medicines. Key stakeholders are actively pursuing diversification into growth areas such as biosimilars, nutraceuticals, consumer healthcare, and contract manufacturing. As Vishal Manchanda from Systematix Group articulates, this shift is not merely an expansion but a strategic pivot towards harnessing new profit pools amid a US generics market that presents limited growth prospects. Indian companies are laying the groundwork for future profitability, although immediate returns may take time as these ventures require sustained investment and gestation periods.
The unpredictable nature of US FDA approvals poses a considerable challenge for Indian drug manufacturers, particularly for complex generics where approval timelines have significantly extended. Companies are maintaining base revenue levels through steady approvals of simpler generic products; however, the broader market anticipates that larger regulatory clearances could take much longer to materialize. The loss of revenue from major generics like Revlimid has compelled players to seek alternative high-value offerings, with biosimilars emerging as a particularly promising sector. Firms such as Biocon, Dr. Reddy’s, and Lupin are cited as frontrunners, with projections indicating that successful biosimilar launches could generate substantial revenue within the next four to five years.
Innovation also stands out as a critical long-term opportunity, necessitating significant initial investment before returns can be realized. Manchanda’s insight highlights that companies like Sun Pharma have begun to carve out substantial positions in this space by launching novel therapies. Meanwhile, the Contract Development and Manufacturing Organization (CDMO) sector has been gaining traction, with large firms such as Divi’s and Laurus potentially positioned to capitalize on a growing trend of outsourcing. The evolution of this sector is especially pertinent as businesses are beginning to shift production away from China towards more localized facilities in India.
Despite initial slower-than-anticipated demand for branded generic GLP-1 products, there remains a strong long-term outlook for this segment, driven largely by improving patient and physician experiences. As the market consolidates, leading companies are expected to capture the majority of market share. Throughout this evolving landscape, Sun Pharma has emerged as a standout investment option, demonstrating strong growth while maintaining an attractive valuation. Overall, while regulatory uncertainties remain, the diversification of India’s pharmaceutical sector into innovative and high-growth areas showcases its potential for future value creation.
Source: The Economic Times
(Expert Note: This report was prepared by the Wealthova team.)